Skip to main content
Safe BPC-157

The people behind a safety claim

BPC-157 reading list

The human reports come first here. The full bibliography follows, including the animal experiments, reviews and agency documents.

Return to the human studies

Human reports

The intravenous safety pilot, interstitial-cystitis pilot and knee-pain case series are the small human reports discussed in McGuire and colleagues' 2025 narrative review. The bladder and knee papers concern local procedures; the infusion paper concerns intravenous exposure.

For my purposes, these procedure differences matter as much as the reassuring absence of reported harm. They limit how readily an observation can travel to another setting.

Animal and cell experiments

For repair, start with the transected rat Achilles tendon and rat sciatic-nerve injury papers. For a proposed mechanism, the VEGFR2 experiment and rat tendon-cell growth-hormone-receptor experiment supply more specific questions. The rat and dog clearance study addresses exposure and metabolism.

The rat spinal-cord injury, gastric-ulcer and acute-pancreatitis organ-injury papers each concern a particular injury model. The brain work separates serotonin synthesis from forced-swim behavior and serotonin-syndrome severity.

Reviews; FDA records

The broader reviews cover literature and patents, intoxication models, cytoprotection and angiogenesis and nitric oxide. They organize existing findings and proposed explanations.

The access record uses FDA's 503A bulk-substance page, significant-safety-risk page, advisory-committee calendar and interim-policy guidance. The legal-status page explains the withdrawal wording and the limits of the advisory record.

Sources

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41. ↗
  6. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Application of Pentadecapeptide BPC 157 Therapy. Curr Issues Mol Biol. 2022;44(5):1901-1927. ↗
  7. Sikiric P, et al. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris. 2000;94(2):99-104. ↗
  8. Boban Blagaic A, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512(2-3):173-179. ↗
  9. Tohyama Y, et al. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004;76(3):345-357. ↗
  10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  11. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. Human pilot data on BPC-157, as summarized in McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Curr Rev Musculoskelet Med. 2025), describing three small human pilot studies: a 2-participant intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot. ↗
  13. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
  14. Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
  15. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Effect Following Intoxications. Pharmaceuticals (Basel). 2025;18(6):928. ↗
  16. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant. Inflammopharmacology. 2025. ↗
  17. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov (verified 2026-05-29). Defines Category 1 and Category 2 and the bulks-list nomination framework. ↗
  18. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov advisory-committee calendar (verified 2026-05-29). Lists BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List. ↗
  19. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA.gov (entry effective 2023-09-29; verified 2026-05-29). Source of the BPC-157 (free base / acetate) Category 2 placement and the stated safety rationale. ↗
  20. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page). FDA.gov (guidance finalized January 2025; verified 2026-05-29). ↗
  21. Access-pathway framework for legally compounded medications under sections 503A and 503B of the FD&C Act (licensed-prescriber evaluation, including compliant telehealth, leading to a valid patient-specific prescription dispensed by a state-licensed 503A pharmacy or sourced from an FDA-registered 503B outsourcing facility; bulk-ingredient eligibility required), as synthesized from FDA compounding guidance. FDA.gov (verified 2026-05-29). ↗
  22. Lee E, Walker C, Ayadi B Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
  23. Lee E, Padgett B Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  24. Author group (2025) BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025. 18:1450. ↗
  25. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. 19:19066-19077. ↗